Teslac
FDA Approves Kadcyla for Late-stage Breast Cancer »
"The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.
HER2 is a protein involved in normal cell growth. It is foun"...
Read the FDA Approves Kadcyla for Late-stage Breast Cancer article »
Teslac
Please Note: This Brand Name drug is no longer available in the US.(Generic versions may still be available.)
CONTRAINDICATIONS
Testolactone is contraindicated in the treatment of breast cancer in men and in patients with a history of hypersensitivity to the drug.
Last reviewed on RxList: 6/30/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Teslac Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Breast Cancer
Find support and advances in treatment.
Updated & New
